Dr. Hugh McTavish, the Company’s Founder and President, is a practicing patent attorney and a Ph.D. biochemist with extensive experience in the laboratory. He is also the inventor of the company’s technology. Dr. McTavish is the lead author of 18 scientific publications, and the inventor of 21 U.S. patents. He also was the nominee of the Independence-Alliance Party for Governor of Minnesota in 2022 and is the author of three books on public policy and nature.
Anne Lynn S. Chang MD, Stanford Medical School, was the Principal Investigator on the Company’s Phase 2 clinical trial.
Prior to joining SquareX, Mr. Kardaras was the Executive Director and Chief Accounting Officer at Imunon, a publicly traded, clinical stage biotechnology company. Previously, he spent over 35 years in leadership positions in finance and accounting at several public and pre-IPO
companies. Mr. Kardaras was also a senior manager at Deloitte where he advised Fortune 500 companies on finance transformation and IPO readiness. He is a CPA who holds an MBA in Finance from New York University’s Stern School of Business and a BA in Economics from Connecticut College.
Dr. Myers is Chairman and CEO of Quoin Pharmaceuticals Ltd., a Nasdaq traded clinical stage, emerging specialty pharmaceutical company, with headquarters in the US, focused on rare skin and orphan diseases for which there are no approved treatments or cures.
Dr. Schwartz serves as an advisor to several early-stage biotechnology companies and is a faculty member at San Jose State University with appointments in the Masters in Biotechnology Program,the Lucas School of Management in the Business College, and the department of Biology.
Thomas D. Horn, M.D., is the co-founder of the company, co-inventor of the company’s technology, and an advisor to Squarex. He is a dermatologist, is on the dermatopathology Faculty at Harvard Medical School, and former Executive Director of the American Board of Dermatology.
Maria Alora Palli, MD, Harvard Medical School, was an Investigator in the Company’s Phase 1 clinical trial and a Principal Investigator in the Company’s Phase 2 clinical trial at Massachusetts General Hospital.
Mr. Danson is a former partner in multiple Big 4 public accounting firms and accomplished C level executive, has over 35 years of experience in international and corporate taxation, financial advisory services including investment banking, mergers and acquisitions, business strategy, and entrepreneurship.
Arkadiusz Dudek, M.D., Medical Advisor and Board member for Squarex, is a practicing physician at Regions Hospital, Saint Paul, MN, and on faculty at the University of Minnesota Medical School. He has previously been on the faculty at the University of Illinois Chicago medical school. He has extensive experience in clinical trial design and is also on the Board of IGF Oncology and other small pharmaceutical companies.
Kathleen Littrell, M.S., is Squarex’s Vice President for Business Development and Clinical Development. She is a scientist and manages the Company’s clinical trials. She has more than 10 years of experience in working of all aspects of clinical trials.